Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Coherus Oncology (CHRS) has disclosed Tax Provisions for 3 consecutive years, with -$380000.0 as the latest value for Q3 2023.

  • Quarterly Tax Provisions changed N/A to -$380000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was -$380000.0 through Dec 2023, changed N/A year-over-year, with the annual reading at -$380000.0 for FY2023, N/A changed from the prior year.
  • Tax Provisions hit -$380000.0 in Q3 2023 for Coherus Oncology, down from $1.1 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.0 million in Q4 2019 to a low of -$380000.0 in Q3 2023.
  • Historically, Tax Provisions has averaged $749125.0 across 3 years, with a median of $890000.0 in 2019.
  • Biggest YoY gain for Tax Provisions was 2437.25% in 2020; the steepest drop was 78.39% in 2020.
  • Year by year, Tax Provisions stood at $2.0 million in 2019, then crashed by 46.9% to $1.1 million in 2020, then tumbled by 135.75% to -$380000.0 in 2023.
  • Business Quant data shows Tax Provisions for CHRS at -$380000.0 in Q3 2023, $1.1 million in Q4 2020, and $183000.0 in Q3 2020.